China has approved early-stage human tests for two experimental vaccines to combat the new coronavirus that killed over 100,000 people worldwide, state media Xinhua reported on Tuesday.
The vaccines are being developed by a Beijing-based unit of Nasdaq-listed Sinovac Biotech, and by the Wuhan Institute of Biological Products, an affiliate of state-owned China National Pharmaceutical Group.
Apple and Google team up on virus ‘contact tracing’ through smartphones
In March, China has the green-light for another clinical trial for a coronavirus vaccine candidate developed by military-backed China's Academy of Military Medical Sciences and HK-listed biotech firm CanSino Bio, shortly after US drug developer Moderna said it had begun human tests for their vaccine with the US National Institutes of Health.
The World Health Organisation said Monday that a safe and effective vaccine would be needed to fully halt the spread of COVID-19, which has killed more than 114,000 people worldwide.
More and more young people are dying from COVID-19, says WHO
"Our global connectedness means the risk of re-introduction and resurgence of COVID19 will continue," Tedros Adhanom Ghebreyesus, WHO Director-General told a virtual briefing from Geneva, stressing that "ultimately, the development and delivery of a safe and effective vaccine will be needed to fully interrupt transmission."
Comments are moderated and generally will be posted if they are on-topic and not abusive.
For more information, please see our Comments FAQ